FDA Accepts Bayer's Application for Label Expansion of Nubeqa
Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.
Bayer shareholders call on CEO to stem the tide of bad news
Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development, to restore confidence and revive the company's share price that hit 20-year lows after its shock warning this week.
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales
BAYRY's third-quarter earnings get affected due to impairment losses at the Crop Science division. Sales gain from the Pharmaceutical business's strong performance.
Bayer Stock: Assessing Upside Potential After Its Q3 Earnings
Bayer faces significant risks from litigation and poor M&As, but its current low valuation presents a potential long-term upside, especially post-2025. Despite recent challenges and a dividend cut, Bayer's fundamentals remain solid, with potential for a 30% annual upside in the long term. Key segments like Consumer Health show promise, but Crop Science and Pharma face headwinds, including generic competition and muted market growth.
Bayer Stock Slumps on Outlook Cut
Bayer shares are falling 11% in German trading after the pharmaceuticals and crop science conglomerate reduced its full-year earnings target and warned of likely lower profit next year amid a tough agricultural market.
Bayer's stock slumps after warning on crop-sciences unit
Bayer's stock slumped on Tuesday as the German giant gave a profit warning on agricultural demand.
Bayer cuts FY operating earnings outlook on weak agriculture markets
Bayer on Tuesday lowered its full-year operating earnings guidance, citing weaker agricultural markets in Latin America.
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU
BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.
Bayer submits EU marketing application for menopause relief drug
Bayer on Tuesday said it had applied for marketing authorization with the European Medicines Agency (EMA) for its menopause relief drug elinzanetant.
Bayer applies for third indication of Nubeqa in EU
Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy.
Bayer must pay $78 mln in latest Roundup cancer trial, jury finds
Bayer must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday.
Bayer shares down 7% after U.S. court says it will review Monsanto case
Shares of German life sciences company Bayer fell more than 7% on Wednesday, after a U.S. court said it would review a case alleging that exposure products made by the company's Monsanto unit harmed individuals. The Washington Supreme Court this week accepted a review of a litigation against the German company over alleged polychlorinated biphenyls (PCBs) exposure at the Sky Valley Education Center.
